RCS - Directa Plus PLC - UK road trial of graphene enhanced asphalt

Directa PlusAnnouncement

08/11/2019 07:05

RNS Number : 7670S
Directa Plus PLC
08 November 2019
 


8 November 2019
 
Directa Plus plc
("Directa Plus" or the "Company")
 
UK road trial of graphene enhanced asphalt
 
Directa Plus (AIM: DCTA), a producer and supplier of graphene-based products for use in consumer and industrial markets, and its partner Iterchimica, an Italian based world leader in products that enhance asphalt performance, are pleased to announce the commencement of a trial of re-surfacing of a section of a UK road with the G+ upgraded asphalt super modifier containing Directa Plus G+ graphene.
 
The trial in Curbridge, Oxfordshire will see the laying of an asphalt concrete with a proprietary innovative graphene-enhanced super modifier and will involve the refurbishment of the two upper layers of a 750m long section of road.  The trial is being conducted with the co-operation of Oxfordshire County Council and the prime contractor is Skanska AB, a multinational construction company.
 
The trial, comparing asphalt concrete with the super modifier to a traditional asphalt surfacing, will assess; service life; resistance to the passage of vehicles; resistance to deformation; and permanent plastic deformation. This follows on from the Company's previously announced successful trials in Italy.
 
The graphene-enhanced super modifier is the result of a three-year research program with a patent filed in 2017. New technologies such as the super modifier has the potential to vastly improve the quality of road surfaces throughout Europe and the wider world.
 
Once laid, asphalt concrete with super modifier can be 100 per cent recycled, which can reduce the extraction of new materials from quarries and first-use bitumen.
 
Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said:
 
"This trial is an important step for Directa Plus and Iterchemica, in partnership, in proving the business and use case for the next generation of graphene enhanced road surfaces.
 
"This technology will allow governments to supply better quality roads for drivers and other road users, at better value for money, and in a more environmentally sustainable way.
 
"Working with leading companies such as Iterchemica to bring the benefits of G+ graphene enhanced products and materials to market is a key part of Directa Plus' strategy across all our key industrial verticals."
 
ENDS
 
For further information please visit http://www.directa-plus.com/ or contact:
 



Directa Plus plc


+39 02 36714458




Giulio Cesareo, CEO


 




Marco Ferrari, CFO


 




 


 




Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)


+44 20 7894 7000




Rick Thompson, Philip Davies, Will Goode (Corporate Finance)


 




Caspar Shand Kydd (Sales)


 




 


 




N+1 Singer (Joint Broker)


+44 20 7496 3069




Mark Taylor, Lauren Kettle, Mia Gardner


 




 


 




Tavistock (Financial PR and IR)


+44 20 7920 3150




Simon Hudson, Edward Lee, Barnaby Hayward


 



 
This announcement has been released by Giulio Cesareo, Chief Executive, on behalf of the Company.
 
About Directa Plus
Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products).  In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products.  All our products are hypoallergenic, non-toxic and sustainably produced.
 
About Iterchimica
Iterchimica, an Italian based world leader in products that enhance both asphalt pavements performance and the laying of road surfaces in order to increase safety, environmental sustainability, and efficiency.
http://www.iterchimica.it/en/
 
-ends-




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGGQWGUPBUQR